TransCode Therapeutics Inc (NASDAQ: RNAZ) is -91.10% lower on its value in year-to-date trading and has touched a low of $0.42 and a high of $356.00 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The RNAZ stock was last observed hovering at around $0.55 in the last trading session, with the day’s gains setting it 0.04%.
Currently trading at $0.59, the stock is 2.05% and -8.43% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.12 million and changing 6.75% at the moment leaves the stock -97.37% off its SMA200. RNAZ registered -99.78% loss for a year compared to 6-month loss of -96.47%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -14.06% gain in the last 1 month and extending the period to 3 months gives it a -24.74%, and is 27.89% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 14.41% over the week and 10.21% over the month.
TransCode Therapeutics Inc (RNAZ) has around 10 employees, a market worth around $3.86M and $0.00M in sales. Distance from 52-week low is 39.76% and -99.84% from its 52-week high. The company has generated returns on investments over the last 12 months (-1104.52%).
TransCode Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.7 with sales reaching -$- over the same period.The EPS is expected to grow by 97.93% this year, but quarterly earnings will post — year-over-year.
TransCode Therapeutics Inc (RNAZ) Top Institutional Holders
The shares outstanding are 6.57M, and float is at 6.54M with Short Float at 0.28%.
TransCode Therapeutics Inc (RNAZ) Insider Activity
The most recent transaction is an insider purchase by Dudley Robert Michael,the company’sChief Executive Officer. SEC filings show that Dudley Robert Michael bought 98,000 shares of the company’s common stock on Sep 28 ’23 at a price of $0.51 per share for a total of $49980.0. Following the purchase, the insider now owns 0.18 million shares.
TransCode Therapeutics Inc disclosed in a document filed with the SEC on Sep 28 ’23 that Fitzgerald Thomas A (Chief Financial Officer) bought a total of 49,350 shares of the company’s common stock. The trade occurred on Sep 28 ’23 and was made at $0.51 per share for $25168.0. Following the transaction, the insider now directly holds 56318.0 shares of the RNAZ stock.
Still, SEC filings show that on Jun 21 ’23, Dudley Robert Michael (Chief Executive Officer) acquired 12,000 shares at an average price of $2.65 for $31818.0. The insider now directly holds 82,262 shares of TransCode Therapeutics Inc (RNAZ).
